Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 11/20 | 0.42 |
| ▸ | CA1 | P00915 | 9/20 | 0.42 |
| ▸ | CA2 | P00918 | 8/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 7/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6402383 | 0.81 | TDP1 (0.51) | TDP1MEN1GAAKMT2ACA12 | |
| SCHEMBL22829019 | 0.78 | TDP1 (0.57) | TDP1MEN1GAAKMT2ACA12 | |
| SCHEMBL16100172 | 0.77 | MEN1 (0.45) | TDP1MEN1GAAKMT2ACA12 | |
| SCHEMBL27093248 | 0.77 | TDP1 (0.51) | TDP1MEN1GAAKMT2ACA12 | |
| SCHEMBL34474320 | 0.77 | TDP1 (0.60) | TDP1MEN1GAAKMT2ACA12 | |
| SCHEMBL3458070 | 0.76 | TDP1 (0.42) | TDP1MEN1GAAKMT2ACA12 | |
| SCHEMBL28432121 | 0.74 | MEN1 (0.42) | TDP1MEN1GAAKMT2ACA12 | |
| SCHEMBL30759450 | 0.74 | TDP1 (0.52) | TDP1MEN1GAAKMT2ACA12 | |
| SCHEMBL192415 | 0.74 | CA12 (0.52) | TDP1MEN1GAAKMT2ACA12 | |
| SCHEMBL27497295 | 0.73 | TDP1 (0.47) | TDP1MEN1GAAKMT2ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062420-A1 | NOVEL DPP1 INHIBITORS AND USES THEREOF | INSMED INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4561565-A2 | NOVEL DPP1 INHIBITORS AND USES THEREOF | Insmed Incorporated (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024026433-A2 | NOVEL DPP1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED (US) | 2024-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062420-A1 | NOVEL DPP1 INHIBITORS AND USES THEREOF | DPP4, DPP3, DPP7 | TDP1 552/4885MEN1 3390/4885GAA 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.